Moderna says its bivalent COVID-19 shot produced a better response against omicron than its booster

Shares of Moderna Inc. were up 2.1% in premarket trading on Wednesday after the company said its experimental bivalent COVID-19 vaccine that targets the original strain of the virus and the omicron variant produced a higher antibody response that its original COVID-19 booster shot one month after administration. The preliminary data from the Phase 2/3 study with 437 participants was shared in a news release. Moderna said it plans to submit the clinical data to U.S. regulators and is then aiming to make this vaccine available in late summer if authorized. The company also said it plans to share additional data about the bivalant vaccine candidate’s response 91 days after vaccination in the coming months. Moderna’s stock is down 42.8% this year, while the broader S&P 500 has declined 12.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.